12 / 25
SUPERVIVENCIA LIBRE DE PROGRESIÓN (SLP)
(VALORACION INDEPENDIENTE)
0.8
1.0
0.6
0.4
0.2
0.0
Progression-free survival
0
3
6
9
12
15
18
21
24
Time, months
Number at risk:
Lenvatinib/everolimus
Lenvatinib
Everolimus
Lenvatinib/everolimus
vs
everolimus
HR=0.45 (95% CI, 0.27–0.79); P=0.0029
Lenvatinib
vs
everolimus
HR=0.62 (95% CI, 0.37–1.04); P=0.12
Median PFS, months
Lenvatinib/everolimus
12.8 (95% CI, 7.4–17.5)
Lenvatinib
9.0 (95% CI, 5.6–10.2)
Everolimus
5.6 (95% CI, 3.6–9.3)
0
0
0
0
1
0
1
4
1
7
5
2
14
9
4
21
21
10
26
27
13
40
40
32
51
52
50
5.6
months
12.8
months
7.2
months
extended median PFS
Motzer RJ, et al.
Lancet Oncol.
Lancet Oncol. 2016;17:e4–5.